Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Adv Exp Med Biol ; 1447: 209-215, 2024.
Article in English | MEDLINE | ID: mdl-38724795

ABSTRACT

There has been an influx of new educational resources for atopic dermatitis (AD) patients in recent years. The two primary organizations in the United States offering educational materials, online resources, and other forms of support include the National Eczema Association (NEA) and the American Academy of Dermatology (AAD). Educational workshops and interventions have emerged as tools that can deliver comprehensive information on AD, such as symptoms, treatments, and disease management. In regard to these workshops, studies have proven longer interventions to be more effective. Studies have also found multidisciplinary teams, including psychologists, dietitians, and AD specialists, to be more effective in AD treatment and education. Additionally, video-based education was found to be the most effective delivery medium compared to various written modes of education. Given the psychosocial impacts of AD, support groups have been found to improve life quality and decrease disease severity, with age-specific groups offering the greatest benefits. Technology such as social media and smartphones has also improved education. Social media has allowed the rapid exchange of information to wider audiences, but due to its unregulated nature, false information has also been disseminated. Despite this, web-based interventions have still been found to be satisfying, convenient, and effective in increasing treatment awareness. The advent of smartphone applications has provided patients with access to information on AD symptoms and treatment on demand. While the effectiveness of these promising applications hasn't been confirmed by studies, patient provider interactions via smartphone (teledermatology) have been found to be as effective as in-person appointments. This chapter will discuss these different types of emerging resources available to AD patients including educational materials, interventions, support groups, organizational support, and technological resources and their effectiveness.


Subject(s)
Dermatitis, Atopic , Patient Education as Topic , Humans , Dermatitis, Atopic/therapy , Patient Education as Topic/methods , Social Media
2.
Aliment Pharmacol Ther ; 49(7): 873-879, 2019 04.
Article in English | MEDLINE | ID: mdl-30773667

ABSTRACT

BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age. METHODS: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites. We examined occurrence of infection or malignancy within 1 year after therapy as our primary outcome. Our efficacy outcomes included clinical remission at 3, 6 and 12 months. Multivariable logistic regression models adjusting for relevant confounders estimated odds ratios (OR) and 95% confidence intervals. RESULTS: The study included 131 anti-TNF and 103 VDZ initiated patients (age range 60-88 years). Approximately half had CD. At 1 year, there were no significant differences in safety profile between the two therapeutic classes. Infections were observed in 20% of anti-TNF-treated and 17% of VDZ-treated patients (P = 0.54). Pneumonia was the most common infection in both groups. While more anti-TNF-treated CD patients were in remission at 3 months compared to VDZ (OR 2.82, 95% CI 1.18-6.76), this difference was not maintained at 6 and 12 months suggesting similar efficacy of both classes. CONCLUSIONS: Both anti-TNF and VDZ therapy were similarly effective and safe in elderly IBD patients.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Gastrointestinal Agents/therapeutic use , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/drug therapy , Tumor Necrosis Factor Inhibitors/therapeutic use , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome
3.
Adv Exp Med Biol ; 1027: 179-184, 2017.
Article in English | MEDLINE | ID: mdl-29063439

ABSTRACT

Atopic dermatitis is a skin condition that is increasing burdensome to patient's lives. Patients require effective strategies to cope with the condition as well as the vast amount of new research that is coming to the forefront. This chapter discusses the patient education aspect of atopic dermatitis. We drew from various sources-such as peer-reviewed academic journals, online groups, and organizational websites-to provide a brief survey of the available types of patient educational resources. We discuss educational materials and interventions, such as workshops and support groups. In addition to the content of the workshops, we also explore the importance of their facilitators. We also review organizations in the US that pertain to atopic dermatitis and eczema care, such as the National Eczema Association and the American Academy of Dermatology. Lastly, we survey the role of technology-such as social media, web-based applications and teledermatology-in facilitating patient education. Despite the promising impacts of these technological interventions in the way patients consume educational materials, we also acknowledge that they are not widely used.


Subject(s)
Dermatitis, Atopic/therapy , Patient Education as Topic , Humans , Self-Help Groups
SELECTION OF CITATIONS
SEARCH DETAIL
...